Cancer-specific administrative data-based comorbidity indices provided valid alternative to Charlson and National Cancer Institute Indices

被引:64
|
作者
Sarfati, Diana [1 ]
Gurney, Jason [1 ]
Stanley, James [1 ]
Salmond, Clare
Crampton, Peter [2 ]
Dennett, Elizabeth [3 ]
Koea, Jonathan [4 ]
Pearce, Neil [5 ,6 ]
机构
[1] Univ Otago, Sch Med & Hlth Sci, Dept Publ Hlth, Wellington 6022, New Zealand
[2] Univ Otago, Fac Hlth Sci, Dunedin 9054, New Zealand
[3] Univ Otago, Sch Med & Hlth Sci, Dept Surg & Anaesthesia, Wellington 6022, New Zealand
[4] North Shore Hosp, Dept Surg, Waitemata Dist Hlth Board, Auckland 0740, New Zealand
[5] Massey Univ, Ctr Publ Hlth Res, Wellington 6022, New Zealand
[6] Univ London London Sch Hyg & Trop Med, Dept Med Stat, London WC1E 7HT, England
关键词
Comorbidity; Multimorbidity; Cancer; Measurement; Validity; Indices; BREAST-CANCER; PROSTATE-CANCER; MEDICAL-RECORD; CO-MORBIDITY; METFORMIN; SURVIVAL; ICD-9-CM; ILLNESS; IMPACT; RISK;
D O I
10.1016/j.jclinepi.2013.11.012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: We aimed to develop and validate administrative data based comorbidity indices for a range of cancer types that included all relevant concomitant conditions. Study Design and Settings: Patients diagnosed with colorectal, breast, gynecological, upper gastrointestinal, or urological cancers identified from the National Cancer Registry between July 1, 2006 and June 30, 2008 for the development cohort (n = 14,096) and July 1, 2008 to December 31, 2009 for the validation cohort (n = 11,014) were identified. A total of 50 conditions were identified using hospital discharge data before cancer diagnosis. Five site-specific indices and a combined site index were developed, with conditions weighted according to their log hazard ratios from age- and stage-adjusted Cox regression models with noncancer death as the outcome. We compared the performance of these indices (the C3 indices) with the Charlson and National Cancer Institute (NCI) comorbidity indices. Results: The correlation between the Charlson and C3 index scores ranged between 0.61 and 0.78. The C3 index outperformed the Charlson and NCI indices for all sites combined, colorectal, and upper gastrointestinal cancer, performing similarly for urological, breast, and gynecological cancers. Conclusion: The C3 indices provide a valid alternative to measuring comorbidity in cancer populations, in some cases providing a modest improvement over other indices. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:586 / 595
页数:10
相关论文
共 32 条
  • [1] Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients
    Marventano, Stefano
    Grosso, Giuseppe
    Mistretta, Antonio
    Bogusz-Czerniewicz, Marta
    Ferranti, Roberta
    Nolfo, Francesca
    Giorgianni, Gabriele
    Rametta, Stefania
    Drago, Filippo
    Basile, Francesco
    Biondi, Antonio
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2014, 29 (09) : 1159 - 1169
  • [2] A systematic review identifies valid comorbidity indices derived from administrative health data
    Yurkovich, Marko
    Avina-Zubieta, J. Antonio
    Thomas, Jamie
    Gorenchtein, Mike
    Lacaille, Diane
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2015, 68 (01) : 3 - 14
  • [3] A Comparison of Charlson and Elixhauser Comorbidity Measures to Predict Colorectal Cancer Survival Using Administrative Health Data
    Lieffers, Jessica R.
    Baracos, Vickie E.
    Winget, Marcy
    Fassbender, Konrad
    CANCER, 2011, 117 (09) : 1957 - 1965
  • [4] Comorbidity and Performance Indices as Predictors of Cancer-Independent Mortality But Not of Cancer-Specific Mortality After Radical Cystectomy for Urothelial Carcinoma of the Bladder
    Mayr, Roman
    May, Mattias
    Martini, Thomas
    Lodde, Michele
    Comploj, Evi
    Pycha, Armin
    Strobel, Jenny
    Denzinger, Stefan
    Otto, Wolfgang
    Wieland, Wolfgang
    Burger, Maximilian
    Fritsche, Hans-Martin
    EUROPEAN UROLOGY, 2012, 62 (04) : 662 - 670
  • [5] Evaluation of four comorbidity indices and Charlson comorbidity index adjustment for colorectal cancer patients
    Stefano Marventano
    Giuseppe Grosso
    Antonio Mistretta
    Marta Bogusz-Czerniewicz
    Roberta Ferranti
    Francesca Nolfo
    Gabriele Giorgianni
    Stefania Rametta
    Filippo Drago
    Francesco Basile
    Antonio Biondi
    International Journal of Colorectal Disease, 2014, 29 : 1159 - 1169
  • [6] Charlson scores based on ICD-10 administrative data were valid in assessing comorbidity in patients undergoing urological cancer surgery
    Nuttall, M
    van der Meulen, J
    Emberton, M
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2006, 59 (03) : 265 - 273
  • [7] Outcome-specific Charlson Comorbidity Indices for Predicting Poor Inpatient Outcomes Following Noncardiac Surgery Using Hospital Administrative Data
    Moodley, Yoshan
    MEDICAL CARE, 2016, 55 (12) : 1082 - 1088
  • [8] Comparing Charlson and Elixhauser comorbidity indices with different weightings to predict in-hospital mortality: an analysis of national inpatient data
    Sharma, Narayan
    Schwendimann, Rene
    Endrich, Olga
    Ausserhofer, Dietmar
    Simon, Michael
    BMC HEALTH SERVICES RESEARCH, 2021, 21 (01)
  • [9] The age-adjusted Charlson comorbidity index is a better predictor of survival in operated lung cancer patients than the Charlson and Elixhauser comorbidity indices
    Yang, Ching-Chieh
    Fong, Yao
    Lin, Li-Ching
    Que, Jenny
    Ting, Wei-Chen
    Chang, Chia-Li
    Wu, Hsin-Min
    Ho, Chung-Han
    Wang, Jhi-Joung
    Huang, Chung-I
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2018, 53 (01) : 235 - 240
  • [10] Utility of prescription-based comorbidity indices for predicting mortality among Australian men with prostate cancer
    Tiruye, Tenaw
    Roder, David
    Fitzgerald, Liesel M.
    O'Callaghan, Michael
    Moretti, Kim
    Beckmann, Kerri
    CANCER EPIDEMIOLOGY, 2024, 88